Every guide, in one place.

The two FDA-approved obesity drugs go head to head — efficacy, side effects, cost, insurance coverage, and who each one is actually right for.

Reports of depression, suicidal ideation, and mood changes on GLP-1s made headlines in 2023-2024. Here's what the FDA found, what the trials show, and what to watch for.

Every GLP-1 carries a black-box warning about thyroid C-cell tumors. It's the most alarming thing on the label — and the most misunderstood. Here's what the data actually shows and who needs to worry.

The oral version of Wegovy was approved in 2026, giving patients a needle-free path to the same molecule. Here's how it compares to the injection, what the pill actually requires, and who it's best for.

Rapid weight loss on GLP-1s can change how your face looks — sometimes dramatically. Here's why it happens, what's normal vs concerning, and what dermatologists and plastic surgeons are actually recommending.

Medicare has historically excluded anti-obesity medications, but the landscape is shifting. Here's the current state of coverage, the new pathways opening up, and what Medicare beneficiaries can actually do today.

PlushCare is in-network with more insurers than any other major GLP-1 telehealth program. We signed up, ran the intake, and tracked the real costs. Here's whether the insurance advantage is worth it.

Ro is one of the biggest names in telehealth. Their GLP-1 weight loss program is fast and slick — but the clinical model and pricing have trade-offs worth understanding before you sign up.

Exercise on a GLP-1 isn't optional — it's the difference between losing weight and getting healthier. Here's how to structure cardio, strength training, and recovery when your appetite is suppressed and your body is changing fast.

Boehringer Ingelheim's survodutide takes a different approach — activating glucagon alongside GLP-1. The result is strong weight loss plus a unique effect on liver fat that could make it the first drug to treat MASH. Here's where it stands.

Appetite suppression is the point of GLP-1 therapy — but it makes hitting protein targets genuinely hard. Here's a practical meal prep system designed for patients who aren't hungry but still need to eat right.

A head-to-head comparison of three popular telehealth GLP-1 programs across pricing, clinical depth, medications offered, and real user experience.

Constipation is one of the most common GLP-1 side effects. Here's why delayed gastric emptying causes it and evidence-based strategies to manage it.

Rapid weight loss on GLP-1s increases gallstone risk. Here's why it happens, warning signs to watch for, and what you can do to reduce your risk.

An independent review of Calibrate's year-long metabolic reset program — pricing, what's included, clinical approach, and whether it's worth $1,500+.

GLP-1 drugs can improve sleep apnea and disrupt sleep patterns. Here's what the research shows and practical tips for better sleep on Ozempic, Wegovy, or Zepbound.

An independent review of Found's telehealth GLP-1 program — pricing, provider quality, medication options, and whether it's worth it vs. competitors.

How long before conception should you stop Ozempic, Wegovy, or Zepbound? Washout timelines, fertility effects, and what the prescribing information says.

Amgen's MariTide is a once-monthly GLP-1/GIP antibody-peptide conjugate in Phase 3 trials. How it works, early results, and what it means for the GLP-1 market.

Protein is the most important macronutrient on a GLP-1. Here's exactly how much you need, why it matters for muscle preservation, and practical strategies to hit your target.

An independent review of Sequence's physician-led GLP-1 program — pricing, clinical model, insurance support, and how it compares to Calibrate and Found.

Realistic weight loss expectations on Ozempic, Wegovy, and Zepbound — month by month from your first injection through year two.

These are the two dominant GLP-1 molecules in 2026. SURMOUNT-5 compared them directly. Here's what the trial showed, what it didn't, and how to decide between them for your situation.

GLP-1 medications must be stopped before pregnancy — but they may actually improve fertility first. Here's the evidence on both sides, the recommended timelines, and why your prescriber needs to be in the loop.

The SELECT trial was the first to prove that a GLP-1 reduces heart attacks and strokes in patients with obesity. Here's what the data shows, who benefits most, and how this changes the insurance and prescribing landscape.

The FDA has resolved the semaglutide and tirzepatide shortages, and the rules around compounded GLP-1s have changed dramatically. Here's the current landscape — what's still available, what's not, and the risks.

For many GLP-1 patients, the most life-changing effect isn't weight loss — it's the silence. The constant mental chatter about food stops. Here's the neuroscience of food noise, how GLP-1s turn it down, and why it matters more than the scale.

Roughly 25–40% of weight lost on a GLP-1 is lean mass — much of it muscle. That number can be cut substantially with the right protein, training, and dosing approach. Here's the protocol that's working in 2026.

The list price is $935/month, but almost nobody pays that. Here's what Ozempic actually costs without insurance — and 6 ways to pay less.

Hair shedding is one of the most upsetting GLP-1 side effects — and one of the most misunderstood. Here's why it happens (the answer is mostly not what you think), how long it lasts, and the interventions that have evidence behind them.

Eli Lilly and Novo Nordisk now both sell their GLP-1 medications directly to self-pay patients. We compared real prices, eligibility rules, and the experience end-to-end. Here's which one wins for your situation.

Mounjaro and Zepbound are the exact same molecule (tirzepatide) made by the same company. So why two names, two prices, and two sets of insurance rules? Here's what's actually going on — and how to use it to your advantage.

Most people regain a meaningful share of lost weight within a year of stopping a GLP-1. Here's what the data actually shows, why it happens, and the four strategies prescribers are using to make discontinuation work.

The week-1 food playbook for GLP-1 users when nothing sounds good. Practical moves that keep nausea down and protein up.

When appetite drops, protein becomes critical. These are the best options to protect muscle on Ozempic and Wegovy.

A non-peptide pill, 15% weight loss, and potentially much cheaper to manufacture. Why Lilly's orforglipron could restructure the GLP-1 market.

No labs, no long intake, shipped in days. Here's what $199/mo gets you — and what it doesn't.

Physician-led, the thorough intake, and real behavioral coaching. Here's what $59/mo + meds actually buys you in 2026.

24% weight loss in Phase 2, three-hormone mechanism, and on track for FDA filing in 2026-2027. Here's what retatrutide actually is and why it matters.

Flat $99/mo with real insurance navigation and a dietitian. Here's what actually arrived in the mail, what we got wrong, and who it's not for.

How tirzepatide works, why its results are dramatically better than semaglutide, and whether the price makes it the right pick for you.

We signed up for every major telehealth program, tracked the real costs, and ranked them by who you actually are — not by who pays us the most.

Same molecule, two brands, wildly different rules. Here's what actually separates them and what it means for cost, coverage, and who should take which.

The pill finally exists. Here's how it compares on results, price, and who should switch — and who definitely shouldn't.